Is There Still a Place for Extraanatomic Axillofemoral Bypass in the Endovascular Era?
British Journal of Surgery · 03.06.2026 · 113 (Supplement_5)
DOI: 10.1093/bjs/znag055.071 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 03.06.2026. Verfasst von F Möhle und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
In an era of rapid advances in endovascular surgery, axillofemoral bypass has become a rare solution for lower limb revascularization.
Aims
This evolution in the indication for axillofemoral bypass makes analyzing outcomes of these procedures even more important.
Methods
Consecutive patients who underwent uni- or bifemoral axillofemoral bypass between March 2018 and May 2024 at a single center were analyzed. Outcomes were primary patency, mortality and major amputation rate at 30 days and one year postoperatively.
Results
Twelve patients were identified. Four (33%) received axillobifemoral bypass, and the remaining patients received axillounifemoral bypass. Median age was 75 (range 57 - 88) years, and 66% were male. All patients had aortoiliac occlusive disease and more than one cardiovascular risk factor. Most patients (75%) were American Society of Anesthesiologists (ASA) category III and three patients (25%) were ASA category IV. Axillofemoral bypass was an urgent procedure in half of the patients due to acute limb ischemia. The other half underwent elective procedures for disabling claudication. Mean operation time was 165 minutes (range 40–309 minutes), and the mean blood loss was 375 mL (range 50–1500 mL). Eight patients (66%) required simultaneous outflow optimization by femoral endarterectomy and patchplasty. One of these patients also received profundopopliteal bypass. Primary patency at 30 days was 100%. One bypass occluded after 10 months, all others were patent at one year. Mortality at 30 days and one year was 8% and 33%, respectively. Two patients (17%) required major amputation within one year of follow-up.
Conclusion
Although axillofemoral bypass surgery has become less common, it may still be a safe and feasible option for polymorbid patients even in emergency situations. Despite the advances in endovascular techniques, we should keep this option in mind.FigureAxillobifemoral bypass in a patient with extended aortoiliac occlusive diseaseFor image description, please refer to the figure legend and surrounding text.
Zitieren
APA
Möhle, F., Müller, D., Weiss, S., & Kissling, P. (2026). Is There Still a Place for Extraanatomic Axillofemoral Bypass in the Endovascular Era?. British Journal of Surgery, 113(Supplement_5). https://doi.org/10.1093/bjs/znag055.071
Vancouver
Möhle F, Müller D, Weiss S, Kissling P. Is There Still a Place for Extraanatomic Axillofemoral Bypass in the Endovascular Era?. British Journal of Surgery. 2026;113(Supplement_5). doi:10.1093/bjs/znag055.071
BibTeX
@article{Mhle2026,
author = {Möhle, F and Müller, D and Weiss, S and Kissling, P},
title = {Is There Still a Place for Extraanatomic Axillofemoral Bypass in the Endovascular Era?},
journal = {British Journal of Surgery},
year = {2026},
volume = {113},
number = {Supplement_5},
doi = {10.1093/bjs/znag055.071}
}
EUVIMED